Factors associated with favorable treatment responses to conventional therapy and tacrolimus in myositis-associated interstitial lung disease were examined in a retrospective cohort study.
Investigators conduct a systematic review to evaluate the risks and benefits of biologics as monotherapy or in combination with methotrexate in patients with rheumatoid arthritis who have not responded to previous biologic treatment.
New guidelines for rheumatoid arthritis treatment with DMARDs and money being steered into lupus research highlight this week’s The Handoff.
Researchers examined the long-term safety of glucocorticoid use in patients with early rheumatoid arthritis, defined as disease duration <6 months, from the multicenter observational Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort.
EULAR has released new recommendations for rheumatoid arthritis management with disease-modifying antirheumatic drugs.
The likelihood of regaining ability to work was studied in patients with rheumatoid arthritis who initiated anti-tumor necrosis factor therapy within 5 years.
Clinical outcomes with higher starting doses of methotrexate were examined in disease-modifying antirheumatic drug-naive patients with early rheumatoid arthritis.
New research pools data from several clinical trials to examine whether tocilizumab-associated neutropenia was linked to increased risk for serious infection in patients with rheumatoid arthritis.
A phase 3 trial examined the superiority of sarilumab monotherapy compared with adalimumab monotherapy in patients who were either intolerant of or inappropriate candidates for methotrexate therapy.
Michael M. Alexiades, MD, met with Rheumatology Advisor to discuss the timely referral of patients with inflammatory arthritides who may be candidates for operative intervention.
